The first study in the UK to directly compare immune reactions between Pfizer's and AstraZeneca's COVID-19 vaccines has found strong and broadly similar antibody responses in people aged over 80 after a first dose of either shot, Reuters news agency revealed on Wednesday.
The study analysed blood samples from 165 people in Britain aged between 80 and 99 who had been given a first COVID-19 vaccine dose.
Scientists who carried out the study also found that T cells, a critical component of the immune system, showed a more enhanced response in those who received the AstraZeneca/Oxford University vaccine compared to those who were given the Pfizer/BioNTech vaccine. The scientists believe that these findings merit further investigation.
Reuters added that this study was published online as a preprint before being peer reviewed. It found that key antibodies were present and at similar levels in 93% of the 76 study participants who were given the Pfizer single COVID-19 vaccine dose and 87% of the 89 participants who received the AstraZeneca shot.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine